API Suppliers
0
US DMFs Filed
0
CEP/COS Certifications
0
JDMFs Filed
0
EU WC
0
Listed Suppliers
0
0
0
USA (Orange Book)
0
Europe
0
Canada
0
Australia
0
South Africa
0
Uploaded Dossiers
0
U.S. Medicaid
0
Annual Reports
0
0
USFDA Orange Book Patents
0
USFDA Exclusivities
0
Blog #PharmaFlow
0
News
EDQM
0
USP
0
JP
0
Other Listed Suppliers
0
0
https://www.globenewswire.com/news-release/2024/06/25/2903722/0/en/Allarity-Therapeutics-Dual-PARP-Tankyrase-Inhibitor-Stenoparib-Continues-to-Show-Extended-Clinical-Benefit-in-Advanced-Ovarian-Cancer.html
https://www.globenewswire.com/news-release/2024/05/14/2881841/0/en/Allarity-Therapeutics-Reports-First-Quarter-Financial-Results-and-Highlights-including-Clear-Clinical-Benefits-from-Phase-2-Trial-NASDAQ-Compliance-and-Significant-Improvement-in-C.html
https://www.globenewswire.com/news-release/2024/05/02/2874113/0/en/Allarity-Therapeutics-Stenoparib-Shows-Clear-Clinical-Benefit-and-Achieves-Significant-Milestone-with-Early-Conclusion-of-Phase-2-Trial-in-Advanced-Ovarian-Cancer.html
https://www.globenewswire.com/news-release/2024/03/27/2853146/0/en/Allarity-Therapeutics-Makes-Strategic-Pivot-to-Focus-Solely-on-Accelerating-Stenoparib-Toward-Regulatory-Approval-in-Advanced-Recurrent-Ovarian-Cancer.html
https://www.globenewswire.com/news-release/2023/12/05/2790791/0/en/Allarity-s-Early-Phase-2-Stenoparib-Data-Indicates-Clinical-Benefit-in-Women-with-Advanced-Ovarian-Cancer-Selected-with-DRP-Companion-Diagnostic.html
https://www.globenewswire.com/news-release/2023/03/20/2630044/0/en/Allarity-Therapeutics-Doses-First-Patient-in-Phase-1b-Clinical-Trial-Evaluating-Dovitinib-and-Stenoparib-Combination-in-Advanced-Solid-Tumors.html